---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055673"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:08:20.149922+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sana Q1 net loss $107.5M; cash $311M after $189.8M financing; four trials on track for 2024

## Summary
- Net loss GAAP $107.5M ($0.49/share) vs $82.1M ($0.43) YoY; adjusted net loss $69.5M ($0.32).
- Cash, equivalents & securities $311.1M (Dec 2023: $205.2M); boosted by $189.8M gross equity offering in Feb 2024.
- Non-GAAP operating cash burn $58.7M in Q1 vs $74.8M YoY; full-year 2024 cash burn guided below $200M.
- Four ongoing clinical programs (SC291, SC262, UP421) across seven indications; initial data expected throughout 2024.
- R&D expenses $56.4M, down 16% from $67.2M, reflecting 2023 strategic repositioning and headcount reduction.

## SEC filing metadata
- accession: 0000950170-24-055673
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000095017024055673/0000950170-24-055673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000095017024055673/sana-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055673
- JSON: https://secwatch.observer/filing/0000950170-24-055673.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055673.txt

## Key facts
- Earnings Releases
  Sana Biotechnology, Inc. reported financial results for the quarter and year ended March 31, 2024.
  - Period: the quarter and year ended March 31, 2024
  - Result: reported results
  source text: On May 8, 2024, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000095017024055673/0000950170-24-055673-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.